| Literature DB >> 35700459 |
Ignacio Martín Santarelli1, Pedro Oscar Manzella2, Francisco Gasco González3, Julián José Ingold4, Melissa Alejandra Olivieri5, Maximiliano Ariel Cloobs Venezia6, Sofía Isabel Fernández7, Marcelo José Melero8.
Abstract
The hepatitis-associated aplastic anemia is one of the acquired bone marrow failure syndromes. It is a stereotyped form of presentation of aplastic anemia and accounts for 2 - 5 % of the cases in the West. Its treatment, which does not differ from that of aplastic anemia, consists of immunosuppression when bone marrow transplant is not possible. Nonetheless, during the SARS-CoV-2 pandemic, recommendations restricting the use of antithymocyte globulin to those cases with the highest risk of death have been issued, since the prognosis of CoViD-19 tends to be worse if administered. We present an otherwise-healthy 18-year-old male who was diagnosed with a hepatitis-associated aplastic anemia and received a personalized treatment following these recommendations. Universidad Nacional de Córdoba.Entities:
Keywords: anemia, aplastic; hepatitis; coronavirus infections
Mesh:
Year: 2022 PMID: 35700459 PMCID: PMC9426336 DOI: 10.31053/1853.0605.v79.n2.35138
Source DB: PubMed Journal: Rev Fac Cien Med Univ Nac Cordoba ISSN: 0014-6722